China Reins In Cancer Drug Trials, Stressing Patient Needs and Benefits
Tougher Comparator Requirements
China's drug regulatory authority is taking aim at strengthening randomized, controlled clinical trials conducted domestically for cancer drugs, leaving biotech stocks reeling from the proposed stricter requirements.
